lystn

Drug Channels was created and is written by Adam J. Fein, Ph.D., one of the country’s foremost experts on pharmaceutical economics and channel strategy. The president of Pembroke Consulting, Inc., and CEO of Drug Channels Institute, Dr. Fein consults with clients in the pharmaceutical and healthcare industries. Eleven of the 15 largest biopharmaceutical manufacturers have relied upon Dr. Fein for his experience, analyses, and insights to help them improve profitability and make better strategic decisions. Click here to read more about Dr. Fein’s industry presence.Dr. Fein excels at unlocking and explaining complex business and economic issues with humor and an accessible, straightforward style, making Drug Channels a popular and authoritative destination for both industry insiders and outsiders. Drug Channels has been cited in such media outlets as The Wall Street Journal and Drug Benefit News, in academic research papers, and across other industry websites.A leader in the pharmaceutical economics blogosphere, Drug Channels has a loyal following of engaged readers. Drug Channels attracts a large, unique, diverse audience throughout the pharmaceutical and healthcare industries. Our readers’ backgrounds reflect the many diverse topics that Drug Channels reports and analyzes. We offer free subscriptions via email, RSS feed, or Twitter. As of January 2013, Drug Channels has nearly 6,000 subscribers via these methods. All articles are also shared with the more than 900 people on Dr. Fein’s personal LinkedIn account. Many key healthcare industries are represented in our readership.ADAM J. FEIN, PH.D.OUR READERS See omnystudio.com/listener for privacy information.